Merkel Cell Carcinoma — Variants & evidence

Merkel Cell Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD274 Expression1
Pembrolizumab	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1578 Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response ra… (full text at CIViC) PMID 27093365 · Nghiem et al., 2016 · Open in CIViC	civic
KIT M541L1
(diagnostic)	Diagnostic	B	Does Not Support Positive	3	submitted	EID9698 Study evaluated 42 cases with aggressive fibromatosis were genotyped for the M541L (c.1621 A>C; rs3822214) was evaluated and compared to gender- and age-matched 126 healthy controls. In 4/7 cases with… (full text at CIViC) PMID 21757432 · Grabellus et al., 2011 · Open in CIViC	civic
PIK3CA P471L1
Idelalisib	Predictive	C	Supports Sensitivity Response	3	accepted	EID739 A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib. PMID 26466009 · Shiver et al., 2015 · Open in CIViC	civic

Data updated 23 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.